Botanix Pharmaceuticals Limited
ASX: BOT
Botanix launches FDA‑approved Sofdra with $0.35 million early revenue.
(Source: TradingView) 3-Month Performance Profile of BOT on a DTF compared to S&P/ASX 200 (XJO).
Botanix Pharmaceuticals Limited has entered a pivotal commercial phase with the U.S. launch of Sofdra (sofpironium) 12.45%, the first and only FDA-approved new chemical entity for pri
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
